The indication was later confirmed by the 2021 ESC Guidelines on cardiovascular disease prevention (i.e. class I indication for GLP1-R in patients with DM2 and atherosclerotic cardiovascular disease to reduce CV and cardiorenal outcomes) [127]. The gene discussed is GLP1R; the disease is myotonic dystrophy type 2.